Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aldeyra Therapeu
(NQ:
ALDX
)
7.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
7.470
Bid (Size)
7.000 (5)
Ask (Size)
8.000 (5)
Prev. Close
7.470
Today's Range
7.470 - 7.470
52wk Range
2.355 - 9.810
Shares Outstanding
58,323,116
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
August 08, 2022
Although US stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Performance
YTD
+74.94%
+74.94%
1 Month
+56.28%
+56.28%
3 Month
+182.95%
+182.95%
6 Month
+76.60%
+76.60%
1 Year
-14.73%
-14.73%
More News
Read More
Recap: Aldeyra Therapeutics Q2 Earnings
August 05, 2022
Via
Benzinga
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
August 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
July 12, 2022
Via
Benzinga
Why Aldeyra Therapeutics' Shares Are Soaring Today?
June 08, 2022
Via
Benzinga
Aldeyra Therapeutics: Q1 Earnings Insights
May 05, 2022
Via
Benzinga
Earnings Scheduled For August 5, 2022
August 05, 2022
Via
Benzinga
Earnings Outlook For Aldeyra Therapeutics
August 04, 2022
Via
Benzinga
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
July 29, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
July 12, 2022
Via
Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
July 12, 2022
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
July 13, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
July 12, 2022
Via
Benzinga
Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
July 12, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
July 11, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
June 09, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
June 08, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
June 07, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics Designates Schirmer Test as Sole Primary Endpoint in Phase 3 TRANQUILITY-2 Trial of Reproxalap in Dry Eye Disease
May 24, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 23, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Aldeyra's Dry Eye Candidate Tops Vehicle In Post-Hoc Analysis Using Computer Automated Grading In Ocular Redness
May 18, 2022
Via
Benzinga
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
May 18, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Via
Benzinga
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
May 05, 2022
From
Aldeyra Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.